malak alshalabi

I've supported biomarker-driven oncology treatment selection at Hikma Pharmaceutical Company through next-generation sequencing testing, biosimilar immunotherapy, and targeted therapy scientific support.

I presented mechanism-of-action, clinical trial, and equivalence data to oncologists, hematologists, and hospital pharmacists while collaborating with medical, regulatory, and commercial teams on accurate scientific messaging.

I'm currently promoting empagliflozin at Dar Al Dawa Pharmaceuticals, translating clinical evidence on glycemic, cardiovascular, and renal outcomes into evidence-based prescribing discussions with physicians. My PharmD and Master's in Global Public Health complement experience across medical representation, pharmaceutical operations, oncology therapeutics, and clinical communication.